Session » SLE – Clinical Poster II: Comorbidities

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1586

All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database

9:00AM-11:00AM: Abstract Number: 1591

Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophophosphamide

9:00AM-11:00AM: Abstract Number: 1597

Assessing Long-term Poor Outcomes in Systemic Lupus Erythematosus Patients with Acute Coronary Syndromes

9:00AM-11:00AM: Abstract Number: 1596

Assessing the Validity of QRISK3 at Predicting Cardiovascular Events in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1565

Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1606

Association of African- American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1626

Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1627

Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure

9:00AM-11:00AM: Abstract Number: 1567

Cachexia in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1570

Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?

9:00AM-11:00AM: Abstract Number: 1574

Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India

9:00AM-11:00AM: Abstract Number: 1590

Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1622

Cognitive Impairments in SLE Negatively Related to Participation and Quality of Life: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1561

Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation

9:00AM-11:00AM: Abstract Number: 1592

Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype

9:00AM-11:00AM: Abstract Number: 1580

Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1598

Disability Among Subtypes of SLE

9:00AM-11:00AM: Abstract Number: 1612

Disease Activity and Cognitive Function in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1588

Disease Activity and Dysregulated Iron Metabolism: A Potentially Overlooked Mechanism for Anaemia in Patients with Systemic Lupus Erythematosus?

9:00AM-11:00AM: Abstract Number: 1616

Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients?

9:00AM-11:00AM: Abstract Number: 1619

Early Vascular Ageing as a Predictor of Future Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1608

Effect of the Metabolic Syndrome on Renal Function Decline in Four Rheumatic Diseases: An 8-year Longitudinal Analysis

9:00AM-11:00AM: Abstract Number: 1585

Endothelial Dysfunction and Arterial Stiffness in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1584

Factors Associated with Accrual of Damage over Time in Patients with SLE: Results from a Multinational Latin American Cohort

9:00AM-11:00AM: Abstract Number: 1618

Factors Associated with Damage Accrual in SLE Patients with No Clinical or Serological Disease Activity

9:00AM-11:00AM: Abstract Number: 1614

Factors Associated with Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 1578

Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1600

Frailty and Sarcopenia in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1593

Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality

9:00AM-11:00AM: Abstract Number: 1566

HER2 as a Biomarker of Proliferative Lupus Nephritis in Children

9:00AM-11:00AM: Abstract Number: 1594

High Expression of CD38 on CD8 T Cells Predicts Increased Burden of Infections in Patients with SLE

9:00AM-11:00AM: Abstract Number: 1568

High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls

9:00AM-11:00AM: Abstract Number: 1605

Homocysteinemia Predicts Renal Insufficiency in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1560

Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus Combined EBV/CMV Viremia

9:00AM-11:00AM: Abstract Number: 1581

Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1573

Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort

9:00AM-11:00AM: Abstract Number: 1563

Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?

9:00AM-11:00AM: Abstract Number: 1613

LDL-cholesterol as a Risk Factor of Progression to ESRD in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1575

Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change

9:00AM-11:00AM: Abstract Number: 1623

Mortality in a SLE Inception Cohort of Hispanic Patients

9:00AM-11:00AM: Abstract Number: 1609

Organ Damage Free Survival in Southern Chinese Patients with Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1587

Oxidized Human Serum Albumin Is Increased in Systemic Lupus Erythematosus, but Not in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1602

Persistency in Platelet C4d and Thrombosis Risk Score Associate with Thrombosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1572

Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors

9:00AM-11:00AM: Abstract Number: 1617

Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1569

Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1610

Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index

9:00AM-11:00AM: Abstract Number: 1579

Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race

9:00AM-11:00AM: Abstract Number: 1576

Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis

9:00AM-11:00AM: Abstract Number: 1589

Prevalence of Cognitive Impairment in an Inception Lupus Cohort as Assessed by a Comprehensive Neuropsychological Battery

9:00AM-11:00AM: Abstract Number: 1601

Prevalence of Peripheral Neuropathy and Its Electrophysiological Types in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1583

Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1624

Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients

9:00AM-11:00AM: Abstract Number: 1564

Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1607

Risk Factors for Avascular Necrosis in SLE: A Multivariate Model

9:00AM-11:00AM: Abstract Number: 1595

Role of Aerobic Exercise in Modulating Fatigue in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1559

Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE

9:00AM-11:00AM: Abstract Number: 1625

Severe Infection Prior to Diagnosis of Systemic Lupus Erythematosus (SLE) Is Associated with Disease-Specific Attributes and Long-Term Comorbidities

9:00AM-11:00AM: Abstract Number: 1558

Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?

9:00AM-11:00AM: Abstract Number: 1603

Stroke Clusters in SLE by Lupus Autoantibodies

9:00AM-11:00AM: Abstract Number: 1611

Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?

9:00AM-11:00AM: Abstract Number: 1620

T-cell Exhaustion in Prolonged Remission SLE Patients

9:00AM-11:00AM: Abstract Number: 1562

The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1582

The Association of Lupus Nephritis Histopathologic Classification with Venous Thromboembolism Is Modified by Age at Biopsy

9:00AM-11:00AM: Abstract Number: 1615

The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement

9:00AM-11:00AM: Abstract Number: 1599

The Impact of Body Mass Index Variability in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1621

The Impact of Disease Activity and Related Factors on Cognitive Dysfunction in SLE

9:00AM-11:00AM: Abstract Number: 1577

The Impact of the New American College of Cardiology/American Heart Association Definition of Hypertension on Cardiovascular Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1604

The Systemic Lupus Erythematosus Cardiovascular Risk Equation

9:00AM-11:00AM: Abstract Number: 1571

Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].